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Background and Aim. The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the
most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD
among HCV infected individuals.Methods. We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV
diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other
causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis
users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used
conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for
having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR)
of total hospital cost and length of stay (LOS) [SAS 9.4]. Results. Our study revealed that cannabis users (CUs) had decreased
prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health
care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was
no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]),
and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of
liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). Conclusions. Our findings suggest that cannabis use is associated
with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations
warrant further molecular mechanistic studies.
1. Introduction
Globally chronic Hepatitis C Infection (HCV), followed by
alcoholic and nonalcoholic-fatty liver diseases (ALD and
NAFLD), represents the most common cause of chronic
liver disease (CLD) that can progress to liver fibrosis and
hepatic cellular carcinoma (HCC) [1]. In the United States
of America (USA), HCV imposes significant financial and
utilization burden on the healthcare system [2]. Fortunately,
with recent advances in HCV therapy using direct-acting
antivirals (DAA) [3], sustained virologic response (SVR)
has been achieved in about 95% of infected individuals
[4], resulting in gradual decline in the burden of HCV [1].
However, the remaining 5% with uncontrolled SVR might
still progress to CLD. Furthermore, individuals who develop
resistance to or do not have access to DAA such as individuals
with modest incomes or from less developed countries are
more likely to still suffer from CLD [5, 6].
Cannabis, the most commonly used illicit drug [7], has
been shown tomodulate inflammatory and fibrotic processes
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in the liver in preclinical studies [8, 9]. These preclinical
observations have additionally been confirmed by recent
population studies on ALD andNAFLD [10, 11]. However, the
relationship between cannabis use andHCVhas been contro-
versial and remains unclear. While earlier studies suggested
that cannabis use resulted in increased steatosis, fibrosis,
and worsening of HCV disease [12–14], recent observations
are now advancing that cannabis use has no effect on HCV
disease progression [15–17]. A recent reports even revealed
that cannabis use was associated with reduced steatosis
in HCV infected individuals [18]. However, most of these
studies had significant limitations given that evaluations were
made from a single center. Further, these studies were limited
in size and lacked diversity in study individuals. Additionally,
these studies often included subjects with other chronic liver
diseases, which might impact the effects of cannabis on HCV
disease study outcomes. Interestingly, a recent study revealed
that cannabidiol (CBD), the main nonpsychoactive agent in
cannabis, induced cell death in approximately 85% of HCV
infected cells in vitro, similar to interferon alpha-2b treatment
[19].
In this study, we examined a large, nationally representa-
tive sample of over 900,000 subjects with chronic HCV infec-
tion.We used propensity-matched analysis with the objective
of eliminating differences in demographics and comorbid
characteristics of study participants. We additionally investi-
gated the relationships between cannabis versus noncannabis
use on the prevalence of liver cirrhosis and liver carcinoma
in our study population. Furthermore, we estimated how
cannabis use affected hospitalization outcomes: mortality,
discharge disposition, cost, and length of stay (LOS).
Our investigations revealed that, among HCV infected
individuals, cannabis use was associated with decreased
prevalence of liver cirrhosis and lower overall treatment cost.
2. Materials and Methods
2.1. Study Population and Design. Our study data included
hospital discharge records of adults (≥18 years old) with
a diagnosis of HCV infection (HCV+). These records are
comprised of hospitalized patients in the USA from 2007 to
2014, archived in the Healthcare Cost and Utilization Project
Nationwide Inpatient Sample (HCUP-NIS) database. HCUP-
NIS is the largest inpatient database in the USA, produced
and maintained by the Agency for Healthcare Research and
Quality (AHRQ) [20]. HCUP-NIS contains about 7-8million
records from over 3,000 nonfederal hospitals across more
than 30 states in the US [20]. Each record has up to 30
different clinical diagnoses, encoded with the International
Classification of Diseases, Ninth Edition, Clinical Modifica-
tion (ICD-9-CM). Our study design is a propensity-matched
cohort study. As the HCUP-NIS is a completely deidentified
and the data is readily available publicly, we did not require
an Institutional Review Board approval.
2.2. Selection of Cannabis Cohort and Propensity Matching
Variables. All clinical attributes were either identified as
variables (demographics, region, and hospital factors) in
the dataset or retrieved from containing variables using
All adult records (age>=18 years) in 2007-2014 HCUP-NIS Data
set with HCV infection (929,535)
Records with chronic HCV (917,936)
Records with chronic HCV without other chronic liver disease
(224,853)
Successfully matched records
Cannabis use (4,728) and Cannabis non-use (4,728)
Records with acute HCV (11,599)
Records with Tobacco, NAFLD, DM, Hyperlipidemia, Obesity,
HBV, Hemochromatosis, PBC, Autoimmune liver disease,
Toxic liver disease, or unspecified liver disorders (610,912)
Records with missing inputs (36,520)
Unmatched Cannabis use (46)
Unmatched Cannabis non-use (177,859)
Records with alcohol use disorder (past or current), alcoholic
hepatitis or alcoholic cirrhosis (254,548)
Chronic HCV records used for propensity matching (188,361)
Cannabis use (4,774) and Cannabis non-use (182,587)
Figure 1: Selection flow chart of study populations. Illustrative
flow chart of how our study population was grouped for statistical
analysis to determine the impact and disease outcomes amongHCV
infected individuals who use cannabis.
the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM). After pooling records
collected from January 1, 2007, to December 31, 2014, in the
HCUP-NIS, we first identified HCV+ (acute and chronic)
records and then eliminated records with acute HCV+,
chronic HCV+ individuals with a history of abusive alcohol
use and diagnosis of alcoholic liver diseases.We also excluded
records with risk factors for CLD or those having other
potential causes of CLD (tobacco use, nonalcoholic fatty
liver disease, diabetes mellitus, hyperlipidemia, obesity, HBV,
PBC, autoimmune liver disease, toxic liver diseases, chronic
passive congestion of the liver, hepatic infarction, hepatitis
from other viral illnesses, and unspecified liver disorders)
(Figure 1). The ICD-9-CM codes used have been utilized to
identify HCV infections and outcomes from the HCUP-NIS
by numerous studies [10, 11, 21–23].
Cannabis users were identified using ICD-9-CM codes,
and this code selects patients using Indian hemp, marijuana,
and different varieties of cannabinoid-containing substances.
We then retrieved data from the NIS on demographics
features including age, gender (male, female), race (White,
Black, Hispanics, and other races), primary health insurance
(Medicare, Medicaid, private, self-pay, and others), income,
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region, and hospital teaching status. Income was stratified
into four based on average household income of the zip-
code of residence. Region was stratified into four based on
US Census Bureau: Northeast, Midwest, South, and West.
Hospital teaching status was classified into three: rural, urban
nonteaching, and urban teaching.
In order to develop a logistic model to predict cannabis
use, we used ICD-9-CM codes to identify various fac-
tors/comorbidities that might be associated with cannabis
usage: peripheral vascular disease, chronic heart failure,
hypertension, chronic lung disease, valvular heart disease,
cardiac arrhythmias, chronic kidney disease, cerebral vascu-
lar disease, ischemic heart disease, hypothyroidism, hyper-
thyroidism, acquired immune deficiency syndrome, other
substance abuse, and malignancies. Some of these variables
were either identified in literature to be associated with
cannabis use or included as general comorbid disorders
common among inpatients.
2.3. Outcome Variables. After matching, we identified 13
outcomes: three primary and ten secondary. Our primary
outcomes were having a diagnosis of liver cirrhosis, liver
carcinoma, and in-hospital mortality. Six of our ten sec-
ondary outcomes are known complications of liver cirrhosis
including ascites, variceal bleeding, hepatorenal syndrome,
hepatic encephalopathy, portal hypertension, and jaundice.
The seventh secondary outcome assessed the proportion of
individuals with decompensated versus nondecompensated
cirrhosis. We deduced cirrhotic decompensation by using
the complications of cirrhosis mentioned above, to stratify
patients based on the Baveno4 methodology. The three other
outcomes were length of stay (LOS), total hospital cost, and
disposition on discharge. All pre-2014 total hospital cost
values were escalated to the 2014 numbers with the inflation
rate. Unfavorable disposition on discharge was defined as
discharge to secondary health facilities versus others (dis-
charged home with/without home health care aide). Besides
mortality, LOS, total hospital cost, and discharge disposition,
which were variables in the dataset, all the other outcomes
were identified using ICD-9-CM codes. The liver cirrhosis
and theBaveno4 system codes have been extensively used and
validated in the NIS [24, 25].
2.4. Statistical Analysis. Continuous variables were rep-
resented with a mean (standard deviation) or median
(interquartile range), depending on the underlying distri-
bution, compared with Mann-Whitney U test; categorical
variables are presented with percentages, compared with
Rao-Scott Chi-square.
After selecting our chronic HCV+ population, we iden-
tified cannabis users and developed a multivariate logistic
regression model, with stepwise negative selection, to gen-
erate propensity scores for cannabis use versus noncannabis
use. With a caliper less than 0.2 of the standard deviation
of the logit of the propensity scores, we used a greedy-
match algorithm (gmatch macro) to match cannabis users
to nonusers in a 1:1 ratio [26]. Propensity matching has been
shown to eliminate a large percentage of residual confound-
ing in observational studies, such as ours, and to generate
effect estimates that are comparable with a randomized
clinical control trial in the magnitude and outcomes [27, 28].
After matching, paired equivalents of the tests above such
as Paired T-test, Wilcoxon signed-rank test, and McNemar’s
test were used to compare differences in outcomes between
cannabis users versus nonusers.
Next, we developed conditional Poisson regression mod-
els, with robustmodification of the error variance, to estimate
the adjusted prevalence rate ratio (adjusted by matching)
[aPRR] of having liver cirrhosis, the complications of liver
cirrhosis including ascites, variceal bleeding, hepatorenal
syndrome, hepatic encephalopathy, portal hypertension, and
jaundice, and other noncirrhotic outcomes: liver carcinoma,
mortality, cost, LOS, and unfavorable discharge to secondary
health facilities [29]. For the noncirrhotic outcomes, we
additionally adjusted for presence of cirrhosis, to eliminate
the confounding effect of cirrhosis on health care utilization,
as cirrhosis has been shown to be the major pathologic
pathway of liver cancer in HCV+ livers and to also contribute
to a significant healthcare utilization. Among individuals
with liver cirrhosis, we designed additional Poisson models
for aPRR for having decompensated versus compensated cir-
rhosis with respect to cannabis exposure, using the Baveno4
classification system. The models were specified to match
the outcomes: gamma for total hospital cost and negative
binomial for LOS to generate the adjustedmean ratios (aMR).
To investigate if the amount of cannabis used had an
impact on the prevalence of liver cirrhosis, we performed
additional analyses. Using the ICD-9-CM codes, we cat-
egorized cannabis users into two groups (dependent and
nondependent users), to loosely approximate the quantity
and frequency of use, since the HCUP-NIS data does not
contain such information. Then we recalculated the effect
of cannabis use on cirrhosis, with Bonferroni adjustment
of the confidence intervals to account for the grouping of
cannabis users. Because our result revealed that the frequency
of cirrhosis remained lower among cannabis users after
matching, we redesigned the propensity matching factors
to include liver cirrhosis, to completely eliminate a possible
confounding effect of cirrhosis in the matched cohort. Then,
we reestimated the health care utilization outcomes, with
respect to cirrhosis. All models used a p-value of <0.05,
reported with a 95% confidence intervals (CI), and were
performed using Statistical Analysis System (SAS V.9.4, SAS
Institute Inc., Cary, NC, US). We plotted the estimates with
GraphPad Prism 7.
3. Results
3.1. Study Population before and after Matching. After elim-
inating records with acute HCV+, abusive alcohol use,
alcoholic liver disorders, other etiologies of chronic liver
diseases, and records with missing inputs, there were 4,774
records with cannabis use disorder out of a total of 188,361
records (Figure 1). Cannabis users were younger (mean age
of 40 years versus 53 years for nonusers), more likely to
be White, to be on Medicaid or Self-pay/Uninsured, and
to be from the lower income quartiles (Table 1). Besides
having higher frequency of other substance abuse and similar
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Table 1: Baseline characteristics of chronic hepatitis C infected patients, by cannabis use status (before propensity matching).
No Cannabis use Cannabis use p-value
n (∼weighted) 182587 (∼887,975) 4774 (∼23,371)
Age, mean (SD) 53.06 (14.15) 40 (12.96) <0.0001
Gender 0.3599
Male 53.86 54.60
Female 46.14 45.40
Race <0.0001
White 59.90 66.23
Black 21.63 18.92
Hispanics 12.74 10.73
Others 5.74 4.12
Health insurance <0.0001
Medicare 33.91 20.92
Medicaid 30.91 46.10
Private 21.00 12.05
Self-pay & others 14.18 20.93
Income <0.0001
Lowest Quartile 38.04 45.92
Second Quartile 24.42 25.41
Third Quartile 20.99 18.50
Highest Quartile 16.55 10.17
Hospital region <0.0001
Northeast 24.99 22.23
Midwest 11.72 15.18
South 39.69 39.21
West 23.60 23.38
Hospital teaching status <0.0001
Rural 7.06 10.35
Urban non-teaching 32.71 33.34
Urban teaching 60.23 56.31
Peripheral vascular disease 2.43 1.05 <0.0001
Congestive heart failure 6.23 2.59 <0.0001
Hypertension 35.92 22.34 <0.0001
Chronic lung disease 16.49 16.21 0.6303
Valvular heart disease 3.14 1.74 <0.0001
Cardiac arrhythmias 10.24 5.29 <0.0001
Chronic kidney disease 12.64 4.49 <0.0001
Cerebral vascular disease 3.45 1.71 <0.0001
Ischemic heart disease 8.68 4.77 <0.0001
Hypothyroidism 7.32 3.65 <0.0001
Hyperthyroidism 0.38 0.38 0.9553
Other substance abuse 15.83 65.38 <0.0001
Malignancies 9.95 3.55 <0.0001
AIDS 2.89 2.59 0.2394
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frequencies for hyperthyroidism and AIDS, cannabis users
had lower percentages for all the other comorbidities. The
frequency of the outcomes of the study including liver
cirrhosis, complications of cirrhosis, mortality, liver cancer,
and unfavorable discharge disposition were all lower among
patients with cannabis use (Table S1).
During propensity matching, 4,728 of 4,774 cannabis
users were successfully matched to an equal number of
nonusers (Table S2). The frequencies of demographic and
comorbid characteristics became statistically identical among
the matched cannabis versus noncannabis users. Further-
more, matching eliminated the aOR for having cannabis use
disorder with respect to different factors (Table S3).
3.2. Outcomes among Propensity-Matched Cohort. After
matching, cannabis users had lower frequencies for liver
cirrhosis and its complications, lower frequencies of higher
Baveno4 scores, and unfavorable discharges. But the fre-
quency of mortality and liver cancer were similar between
cannabis users and nonusers (Table 2). On regression analysis
(Table 3 and Figure 2), when compared to nonusers, cannabis
users had lower prevalence rate ratio for liver cirrhosis
(aPRR:0.81[0.72-0.91]). They had a cirrhosis prevalence rate
of 40.18 per 1,000 hospitalizations versus 49.72 per 1,000
hospitalizations among nonusers (Table 4). Furthermore,
cannabis users had decreased frequencies of ascites and portal
hypertension, while other complications of cirrhosis were
similar across noncannabis users. The adjusted prevalence of
liver cancer and in-hospital mortality was similar across both
cannabis and noncannabis user groups. While the LOS was
similar among both groups (5.57[5.10-6.09] versus 5.66[5.25-
6.10] days), cannabis users had decreased total hospital cost
($39,642[36,220-43,387] versus $45,566[$42,244-$49,150])
and less unfavorable discharge disposition (0.87[0.78-0.96]).
3.3. Post Hoc Analyses. After categorizing cannabis users
into two groups (dependent and nondependent users), we
found that the prevalence of liver cirrhosis decreased by
15% and 48% among nondependent (0.85[0.73-0.99], p-
value: 0.0272) and dependent users (0.52[0.35-0.79], p-value:
0.0004), respectively. Further, compared to nondependent
cannabis users, dependent users had a 38% decreased preva-
lence of liver cirrhosis (0.62[0.41-0.93], p-value: 0.0156).
After redesigning the propensity matching with cirrhosis
as a predictor of cannabis use, the associations between
cannabis use and healthcare utilization was similar to the
previous model, which did not match with cirrhosis, but
adjusted for cirrhosis as a predictor (Table S4).
4. Discussion
Our study utilizing a large dataset spanning records from
2007 to 2014 of NIS revealed novel associations between
cannabis use and chronic liver disease among HCV infected
individuals. Using propensity matching to effectively elim-
inate many confounding differences, our studies revealed
that cannabis use was associated with more favorable HCV
infection outcomes. Compared to other population studies
performed before 2010, which all suggested that cannabis use
resulted in steatosis and cirrhosis among HCV [12–14], our
results revealed the contrary. These three earlier studies had
limited sample sizes (204, 270, and 315 subjects) and included
patients with alcohol and tobacco use, which might have
resulted in a different outcome compared to our study.
Cannabinoids act through CB-1 and CB-2 receptors, with
pro- and antifibrotic effects respectively. Early studies mostly
rationalized with the fact that HCV was associated with a
significant induction in hepatic CB-1 receptor expression
[30]. However, later studies between 2013 and 2016 among
HCV [16] or HCV+HIV [15, 17] coinfected individuals
concluded that cannabis had no effect on liver disease from
HCV. Although these three newer studies had larger samples
sizes (550, 575, and 690 subjects), they did not eliminatemany
chronic liver diseases from diverse etiologies. Further, a more
recent study on HCV+HIV coinfected patients in 2017 [18]
used an even larger sample size (838 subjects) and revealed
that cannabis use was associated with a decrease in hepatic
steatosis. Our analysis extended on these previous studies
in an attempt to overcome limitations of sample size and
inclusions of liver disease fromnon-HCV infection and other
synergistic etiologies. We also excluded other causes of CLD
and used a more recent nationally representative dataset.
Further, we additionally investigated a larger array of clinical
outcomes and health care utilization indicators.
Cannabinoids have been demonstrated to kill profibrotic
hepatic stellate cells [31] and reverse liver fibrosis/cirrhosis in
preclinical models after chronic administration [32]. These
actions might explain our findings of decreased hepatic
cirrhosis and its attendant complications, which are all
secondary to portal hypertension from cirrhosis. Likewise,
cannabigerol, a nonpsychotropic component of cannabis
thwarts the growth of colorectal cancer cells [33], and tetrahy-
drocannabinol inhibited glioblastoma cell growth both in
vitro and in patients [34]. Both of these mechanisms and
decreased prevalence of cirrhosismight explainwhy cannabis
users had lower prevalence of liver carcinoma.
We reveal that cannabis was associated with reduced
unfavorable discharge and hospital cost. These outcomes
might be due to less burden of CLD because of the smaller
frequency of cirrhosis and carcinoma. Cannabis has been
shown to be related to lower mortality among hospitalized
cancer patients [35].
In summary, the effect of cannabis onHCVdisease might
bemultifaceted. First, cannabismight be directly toxic to hep-
atitis virus in vivo, as is recently shown in vitro [19]. Second,
cannabis users might make HCV patients feel less nauseous
and more motivated to take their other antiviral medications
and another medical regimen [36]. Third, cannabis might
be associated with decreased hepatic cirrhosis and compli-
cations of cirrhosis, thereby resulting in the lower cost and
better discharge disposition outcomes among cannabis users.
Thee potential roles played by cannabis use on liver disease
progression in HCV positive patients will require additional
complementary evaluation by way of prospective studies.
4.1. Study Strengths and Limitations. The major weaknesses
in our study are the cross-sectional design, recall biases, cod-
ing errors in the ICD-9-CM application, lack of information
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Table 2: Outcome characteristics by cannabis use status, after propensity matching.
No Cannabis use Cannabis use p-value
n 4728 4728
Liver cirrhosis 10.55 8.52 0.0014
Ascites 4.51 2.79 <0.0001
Variceal bleeding 1.57 1.61 0.0258
Hepatorenal syndrome 0.49 0.38 0.4329
Hepatic encephalopathy 0.59 0.40 0.1964
Portal hypertension 2.92 2.07 0.0108
Jaundice 0.53 0.34 0.158
Baveno4 scoring 0.0019
0: No cirrhosis 89.45 91.48
1: Compensated cirrhosis 5.31 4.72
2: Decompensated cirrhosis 5.25 3.81
Mortality 1.65 1.27 0.119
Liver cancer 1.31 1.04 0.2282
Discharge disposition 0.0014
Favourable discharge 80.71 83.27
Unfavourable discharge 19.29 16.73
Table 3: Comparison of liver disease and outcomes among HCV patients.
aPRR/aMR LCL UCL p-value
Liver cirrhosis 0.81 0.72 0.91 0.0004
Liver cancer∗ 0.79 0.55 1.13 0.2013
Complications of cirrhosis
Ascites 0.62 0.50 0.76 <0.0001
Variceal bleeding 1.03 0.75 1.40 0.8658
Hepatorenal syndrome 0.78 0.42 1.45 0.436
Hepatic encephalopathy 0.68 0.38 1.20 0.1824
Portal hypertension 0.71 0.56 0.91 0.0065
Jaundice 0.64 0.34 1.20 0.1633
Baveno4 0.97 0.93 1.02 0.2167
Health care utilization
Inpatient mortality∗ 0.84 0.60 1.17 0.298
Length of stay∗ 0.99 0.93 1.05 0.6319
Total hospital cost∗ 0.87 0.80 0.95 0.0012
Unfavourable discharge∗ 0.85 0.77 0.95 0.0025
aPRR: adjusted prevalence rate ratio; aMR: adjusted mean ratio (LOS and total hospital cost). LCL and UCL: lower and upper confidence limit; ∗: effects are
after adjusting for cirrhosis.
Table 4: Adjusted estimates of liver disease, mortality, and outcomes of HCV patients.
Cannabis use No Cannabis use
Prevalence LCL UCL Prevalence LCL UCL
Cirrhosis 54.8 48.29 62.18 67.85 60.66 75.89
Cancer∗ 3.265 1.819 5.859 4.131 2.356 7.243
Mortality∗ 1.741 1.194 2.536 2.078 1.486 2.907
Mean LCL UCL Mean LCL UCL
LOS, days 5.5762 5.104 6.092 5.6611 5.251 6.103
Charge, $ 39642 36220 43387 45566 42244 49150
Percentage LCL UCL Percentage LCL UCL
Unfavourable discharge 25.18 22.28 28.46 29.57 26.3 33.26
LCL and UCL: lower and upper confidence limit.
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Figure 2: Summary schematic of the effects of cannabis use by HCV infected individuals and liver disease associated parameters. Our
observations suggest that cannabis use by HCV infected individuals is associated with significant reduction in adverse progressive disease
associated pathologies. Further, cannabis users had an overall lower cost of disease management compared to noncannabis users. Schematic
illustrations made use of some motifolio templates (http://www.motifolio.com/).
on medications such as antiviral therapies, type of cannabis
ingested, mode of cannabis use (oral versus inhalation), and
sensitivity and specificity of ICD-9-CM coding for cannabis
use disorder. Absence of data on which patients received the
new direct-acting antiviral therapy is a significant limitation,
given that these medications are extremely effective and
significantly modulate the progress of HCV liver disease.
We mitigated many of these errors by first eliminating other
causes of CLD and using a propensity-matched analysis,
which directly balanced and eliminated the effect of factors
associated with cannabis use in the NIS and allowed a less
biased estimation of our outcomes. However, it is possible
that additional unmeasured confounding factors might still
impact our observations. These errors are likely to similarly
impact both cannabis and noncannabis use groups andwould
likely decrease our observed effects on cannabis use and the
incidence of CLD. Therefore, the true effect of cannabis use
on HCV might be stronger than observed estimates in our
current study. Furthermore, the large size of the NIS data
allowed us to conduct a very efficient propensity matching
and to capture subjects from all over the USA, making our
result more generalizable.
5. Conclusions
Our novel study to the best of our knowledge represents
the largest population-based study to assess the effect of
cannabis use on CLD associated with HCV infection. Our
observations suggest cannabis use might have a positive
impact in alleviating complications of portal hypertension,
liver cancer, and disease outcomes among HCV infected
individuals. These novel findings require additional prospec-
tive and translational molecular research studies to decipher
which specific active components of cannabis impact liver
disease development during chronic HCV infection.
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Abbreviations
AC: Alcoholic cirrhosis
AH: alcoholic hepatitis
ALD: Alcoholic liver disease
AS: Alcoholic steatosis
CBD: Cannabidiol
CLD: Chronic liver disease
CU: Cannabis use
HBV: Hepatitis b viral infection
HCC: Hepatocellular carcinoma
HCV: Hepatitis c viral infection
THC: Tetrahydrocannabinol.
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